Company Analysis

Pliant Therapeutics, Inc. (PLRX)

Nasdaq: PLRX · Pharmaceutical Preparations · South San Francisco, CA · filing with the SEC since 2018
Grade4.7
◀ Past 4.4● Present 5.4▶ Future 4.3
4 est.

Filings

222 filings since 2017 beside 218 insider forms · Non-accelerated filer and smaller reporting company · read from EDGAR on Nov 13, 2026
Due nextNon-accelerated filer and smaller reporting company
10-K Annual report for the fiscal year ending Dec 31, 2026Non-accelerated filers and smaller reporting companies have 90 days after the fiscal year ends. by Mar 31, 2027
10-Q Quarterly report for the quarter ending Mar 31, 2027Non-accelerated filers and smaller reporting companies have 45 days after the quarter ends; quarter ends are taken to the month end. by May 15, 2027

A deadline is the latest date the SEC's rules allow for its filer category. It is not a forecast of the day the company files. Last time, the results release (8-K item 2.02) came 43 days after the quarter ended. The proxy statement was last filed Apr 22, 2026.

Filings a yearinsider forms included
757496484665853
20192020202120222023202420252026

2026 counts to Nov 13, 2026.

Officer or director change (8-K item 5.02): 7 times in the last 36 months, the newest Jul 13, 2026.SEC letters: 2 in the last 36 months, the newest Apr 2, 2026.
Insider forms 218

Insider forms (3, 4, 5 and 144) are counted each year but not listed here; the people and their trades are on the Ownership tab.

FiledFormWhat it is, in plain wordsPeriodAsk
Nov 12, 2026 8-K items 2.02, 9.01 Results released · Current report
Nov 12, 2026 10-Q Quarterly report Sep 30, 2026
Aug 14, 2026 SCHEDULE 13G Large holder notice
Aug 14, 2026 SCHEDULE 13G/A Large holder update, amended
Aug 11, 2026 8-K items 2.02, 9.01 Results released · Current report
Aug 11, 2026 10-Q Quarterly report Jun 30, 2026
Jul 13, 2026 8-K item 5.02 Officer or director change · Current report Jul 9, 2026
Jun 11, 2026 8-K item 5.07 Shareholder vote · Current report
May 11, 2026 10-Q Quarterly report Mar 31, 2026
May 11, 2026 8-K items 2.02, 9.01 Results released · Current report
Apr 22, 2026 ARS Annual report to shareholders Dec 31, 2025
Apr 22, 2026 DEFA14A Extra proxy material
Apr 22, 2026 DEF 14A Proxy statement Jun 11, 2026
Apr 17, 2026 8-K item 5.02 Officer or director change · Current report Apr 14, 2026
Apr 6, 2026 EFFECT Registration effective
Apr 2, 2026 CORRESP Reply to the SEC
Apr 2, 2026 UPLOAD SEC comment letter
Mar 30, 2026 8-K item 8.01 Other event · Current report Mar 27, 2026
Mar 30, 2026 S-3 Shelf registration
Mar 11, 2026 S-8 Employee stock plan registration
Mar 11, 2026 8-K items 2.02, 9.01 Results released · Current report
Mar 11, 2026 10-K Annual report Dec 31, 2025
Mar 3, 2026 8-K items 1.01, 3.03, 9.01 Major agreement signed; Change to shareholders' rights · Current report
Feb 17, 2026 SCHEDULE 13G/A Large holder update, amended
Feb 17, 2026 SCHEDULE 13G/A Large holder update, amended
Feb 9, 2026 SCHEDULE 13G Large holder notice
Jan 30, 2026 SCHEDULE 13G Large holder notice
Jan 22, 2026 SCHEDULE 13G Large holder notice
Jan 8, 2026 SCHEDULE 13G/A Large holder update, amended
Dec 16, 2025 8-K item 5.02 Officer or director change · Current report Dec 10, 2025
Dec 8, 2025 8-K item 5.02 Officer or director change · Current report Dec 2, 2025
Nov 14, 2025 SCHEDULE 13G/A Large holder update, amended
Nov 14, 2025 SCHEDULE 13G Large holder notice
Nov 6, 2025 10-Q Quarterly report Sep 30, 2025
Nov 6, 2025 8-K items 2.02, 9.01 Results released · Current report
Oct 24, 2025 8-K item 5.02 Officer or director change · Current report Oct 20, 2025
Oct 20, 2025 8-K item 1.02 Major agreement ended · Current report Oct 14, 2025
Sep 4, 2025 SCHEDULE 13G Large holder notice
Aug 14, 2025 SCHEDULE 13G/A Large holder update, amended
Aug 7, 2025 10-Q Quarterly report Jun 30, 2025
40 of 222 shown

Every row opens the filing on EDGAR. The plain words are the site's own for each form and each 8-K item; the complete history, insider forms included, is on EDGAR.

SI Assistanton PLRX · research, not advice